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Background: In 2009, Dr. Paolo Zamboni proposed chronic cerebrospinal venous insufficiency (CCSVI) as a possible
cause of multiple sclerosis (MS). Although his theory and the associated treatment (“liberation therapy”) received
little more than passing interest in the international scientific and medical communities, his ideas became the
source of tremendous public and political tension in Canada. The story moved rapidly from mainstream media to
social networking sites. CCSVI and liberation therapy swiftly garnered support among patients and triggered
remarkable and relentless advocacy efforts. Policy makers have responded in a variety of ways to the public’s call
for action.
Discussion: We present three different perspectives on this evolving story, that of a health journalist who played a
key role in the media coverage of this issue, that of a health law and policy scholar who has closely observed the
unfolding public policy developments across the country, and that of a medical ethicist who sits on an expert
panel convened by the MS Society of Canada and the Canadian Institutes of Health Research to assess the
evidence as it emerges.
Summary: This story raises important questions about resource allocation and priority setting in scientific research
and science policy. The growing power of social media represents a new level of citizen engagement and
advocacy, and emphasizes the importance of open debate about the basis on which such policy choices are made.
It also highlights the different ways evidence may be understood, valued and utilized by various stakeholders and
further emphasizes calls to improve science communication so as to support balanced and informed decision-
making.
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Science policy in general and health policy in particular
emphasize the necessity of being evidence based. At the
same time, the need to engage members of the public in
open discussion about fundamental issues that could
affect their well-being has been gaining traction in recent
years. “Public participation,” “citizen engagement,” “delib-
erative democracy,” and related notions are now part of
the science and health policy lexicons. But it is one thing
to engage citizens about a particular policy issue, such as
whether they would participate in a biobank, and if so,
what in their view would constitute appropriate consent
[1,2]. It is quite another to have the public at large set the* Correspondence: dpullman@mun.ca
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reproduction in any medium, provided the orpolicy agenda by first dictating specific questions that
science should address, and then passing judgment
upon what constitutes “evidence” in support of a par-
ticular conclusion. The advent of social media in recent
years is changing the dynamics of the relationship be-
tween scientists, politicians, health professionals and
the public at large. Special interest groups now use
these tools to gather and disseminate information about
key issues, and to exert pressure on various bodies to
advance their agendas. The broader implications this
growing trend has for what constitutes evidence based
science and health policy are just beginning to emerge.
This paper addresses some aspects of this dynamic as
it has played out over the past three years in Canada
with regard to a controversial new treatment for mul-
tiple sclerosis (MS). MS is a neurodegenerative diseasel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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protective covering around the nerve cells in the brain
and spinal cord. There is no consensus about its cause.
While MS is often characterized as an autoimmune dis-
order, other potential theories relate to toxins, environ-
mental triggers, vitamin D deficiency, infectious agents,
genetics and vascular abnormalities. Common symptoms
include visual disturbance, speech problems, numbness,
pain, loss of balance, loss of coordination, bladder and
bowel problems, stiffness, weakness, paralysis and fatigue.
Symptoms vary widely from person to person and
throughout the course of the disease. While current treat-
ments can decrease the severity and frequency of MS
attacks and may slow disease progression, many treat-
ments are associated with significant side-effects. There is
no proven cure [3].
Given the potentially devastating impact of MS and
the continuing bewilderment and speculation as to its
cause, it is little wonder that general excitement ensued
when Dr. Paolo Zamboni, an Italian vascular surgeon,
announced he may have discovered a key cause of the
disease. Based on the results of a study conducted in his
clinic, Zamboni theorized that MS is caused by narrowed
or blocked veins in the neck which prevent the efficient
removal of blood from the brain and spinal cord. Zamboni
speculates this condition leads to a build-up of iron, which
in turn triggers the inflammation and myelin degeneration
seen in MS sufferers [4]. Chronic cerebrospinal venous in-
sufficiency (CCSVI) is now part of the MS vernacular to
describe this putative cause. CCSVI is diagnosed by ultra-
sound and treated surgically by balloon angioplasty, or by
the insertion of stents to keep the veins open. Zamboni
coined the term “liberation therapy” to describe this un-
precedented treatment, and has called for randomized
trials to assess its effects more rigorously.
Zamboni’s theory was contentious from the beginning,
in part because the initial study that received so much
attention was a non-randomized, non-blinded study of
65 patients. With no controls for placebo effect or to
account for spontaneous improvements common to the
relapsing-remitting form of MS, there was much
skepticism in scientific and medical communities as to
the validity of his results. Indeed subsequent studies
were unable to replicate Zamboni’s original findings
[5,6]. Concerns were raised as well about potential risks
associated with the proposed therapy including possible
hemorrhage, dislodgment of blood clots resulting in
heart attack or stroke, nerve damage in the neck, com-
plications at the puncture site and vessel puncture by
the catheter, among others [7]. Nevertheless, clinics
around the world started offering liberation therapy [8],
and many desperate MS sufferers became medical tour-
ists, investing considerable time, effort and financial
resources in the hope of a cure [9].In most jurisdictions, mainstream medicine has treated
Zamboni’s proposed diagnosis and treatment as little
more than a curiosity. Such has not been the case in
Canada. For reasons that are still not entirely clear, CCSVI
has become a rallying point for many in the Canadian MS
community. Despite the risks and the equivocal state of
the evidence, the suggestion that MS may have physio-
logical origins with a surgical solution has triggered a
flurry of media coverage [10], ignited the hopes of
patients and their families, and divided the community
of MS specialists [11]. The MS Society of Canada, the
Canadian Medical Association, and the Canadian Institutes
of Health Research (CIHR) have all urged caution and the
need for further investigations to establish a solid eviden-
tiary basis for the CCSVI diagnosis and liberation therapy.
Nevertheless, countless MS patients and their supporters
in Canada have formed advocacy groups and used the
internet and social media to advocate for clinical trials and
in support of venoplasty as a treatment they insist should
be covered under the publicly funded health care system
[8]. Advocates often attack the credibility of those who
express skepticism about CCSVI, or who call for a caution-
ary approach [10]. It has been suggested that “[p]erhaps for
no other condition has social media been as effective in
promoting a medical theory as with chronic cerebrospinal
venous insufficiency” [12].
In what follows we share some of our experiences and
insights with regard to the CCSVI/Liberation Therapy
phenomenon as it continues to unfold in Canada. We
characterize our perspectives as “from the trenches” as
each of us, to some degree, has played a role or other-
wise been engaged in this continuing saga as it has
unfolded in the Canadian context. AP is a health jour-
nalist for the Globe and Mail, Canada’s national news-
paper. He played a key role in this breaking story and
has commented extensively on it as it has continued to
unfold. AZ is a health law and policy expert located in
Saskatchewan, the Canadian province that has acted
most aggressively with regard to CCSVI. DP is a member
of an expert panel convened by the MS Society of
Canada and the CIHR to oversee a number of studies
designed ostensibly to assess the CCSVI-MS hypothesis
and to establish whether an evidentiary basis exists to
justify proceeding with a clinical trial. The work of this
panel has been closely scrutinized and the political pres-
sure to proceed with a clinical trial has been palpable.
Discussion
Politics and publicity—André Picard
On November 21, 2009, the CTV network’s flagship
newsmagazine broadcast a story entitled “The Liberation
Treatment: A Whole New Approach to MS” [13]. The
same day, The Globe and Mail (part of the same media
conglomerate) published a companion story entitled
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based on the documentary [14]. It was not your typical
90 second TV news story, but a 30-minute documentary,
months in the making. The story focused on Zamboni’s
work and the timing of the documentary was pegged to
the publication of his research in a peer-reviewed jour-
nal, but also emphasized the source of the doctor’s quest
to find a cure—his wife is afflicted with MS. The CTV
documentary had all the elements of a good news, labor
of love story.
Zamboni became interested in MS in 1999 when his
wife was diagnosed with the condition. He set out to
learn all he could about MS and was initially intrigued
about repeated references, dating back a century, to the
possibility that iron build-up might be a contributing
factor. Zamboni’s primary area of research was related to
how heavy metals like iron damage blood vessels in the
leg; he wondered if there could be a similar problem
with blood vessels in the brain. Using ultrasound scans,
Zamboni discovered vein blockages and abnormalities in
all the MS patients he tested. He wondered if clearing
blockages in the neck could alleviate symptoms and
received ethics approval to conduct a procedure similar
to angioplasty on patients. The CTV documentary
showed patients before, during, and after the surgery, their
MS symptoms seemingly alleviated. Even Zamboni’s wife
had the surgery, giving the story a lovely romantic touch.
So, yes, the initial story about CCSVI was powerful
and enthusiastic. But the story also cautioned that
“evidence is too scant and speculative to start rewrit-
ing medical textbooks” and that “MS sufferers should
not rush off to get the surgery” [14]. Missing, how-
ever, were images of skeptics and opponents of the
CCSVI theory. The MS Society of Canada refused to
go on camera, instead issuing a short written state-
ment urging caution. Some physicians who specialize
in MS believed the theory was quackery but did not
want to be quoted for fear of giving the idea any cre-
dence. They would later become the fiercest critics of
the media treatment of the story.
Where CCSVI really took off though was in the blogo-
sphere. There, the provisos evaporated and the “liberation”
treatment was billed as a miracle cure. Testimonials con-
tinued to pile up.
Patients began to clamor for the surgery and under-
standably so, as traditional treatments for MS are often
frustratingly ineffective. Many were willing to invest
their life savings, and clinics—in Poland, in Costa Rica,
in Bulgaria—were more than happy to take their money.
The initial reports from patients fuelled the hype, and
increasingly breathless media coverage. Those crippled
by MS began walking, seemingly on water. Those who
urged caution were shouted down, often dismissed as
pawns for Big Pharma. There were demands for theliberation procedure to be funded in Canada. Health
ministers vowed to finance research.
Meanwhile, science took its course, and so did jour-
nalism. Researchers cautiously tried to reproduce Dr.
Zamboni’s initial findings. Zamboni himself joined the
chorus urging a go-slow approach; while he was enthu-
siastic about the procedure he cautioned that vein
blockage was not the sole cause of MS and urged more
research to better understand the potential risks and
benefits. These developments were chronicled in some
detail in the mainstream press [15].
Then less rosy reports about liberation surgery began to
surface. Veins collapsed in about half of those who under-
went angioplasty and stents were required. Patients
initially felt better. Then, weeks after the procedure,
blockages reappeared; many suffered dangerous blood
clots, a common side effect of stenting. In November
2010, Mahir Mostic, a 35-year-old Canadian, died after
undergoing the procedure [16]. That was a turning point.
Subsequent media coverage became both more cautious
and more skeptical.
But CCSVI had momentum, particularly political mo-
mentum. There has been much criticism of elected offi-
cials for funding CCSVI research. But they were under
tremendous pressure; MS patients are well-organized,
vocal and, in many cases, desperate. Given that the trad-
itional treatment for MS involves very expensive drugs,
one of the powerful undercurrents of the story was a be-
lief that those who opposed further research were in the
back pocket of Big Pharma. Time and again we were
reminded that the researchers who discovered that
stomach ulcers were caused by H. pylori bacteria were
treated as quacks by mainstream medicine, and espe-
cially by surgeons who made a living doing ulcer
surgery.
There is also, in the CCSVI narrative, a belief that
there are two camps: MS patients pushing for an un-
proven intervention and scientists who opposed them.
The reality is more complex. Patients were deeply
divided. Clinicians and scientists also had a vast array of
opinions, ranging from those who believed CCSVI had
some validity [17] through to those that believed
research should be funded to provide a definitive answer,
and on to those who held that the theory was biologic-
ally implausible. All appealed to some semblance of
“evidence” to back their positions.
Of course “evidence” means starkly different things to
different people. Evidence, to academics and scientific
researchers, means carefully gathered data that is ana-
lyzed and interpreted through a rigorous process with
established norms. This no doubt accounts in part for
the cautious approach that characterized the scientific
community’s initial response to this story. However, for
some in the research establishment, evidence consists
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or serves their purposes. There are a lot of biases that
taint interpretation of evidence. Let’s not forget that
medical journals tend to publish only positive studies,
not negative ones, particularly when it comes to research
on drugs. That their advertising derives principally from
pharmaceutical company ads is, no doubt, merely a
happy coincidence.
For the public and patients, the most powerful evi-
dence is often anecdotal, and the CCSVI story provided
a lot of powerful anecdote, written and visual. For poli-
ticians, the most powerful evidence is too often that
which is stated loudest and, again, the cries for help
from the MS community were loud, and understand-
ably so.
And what is evidence for journalists? It can be any
combination of the above. Journalists love anecdote—
particularly heart-wrenching stories; and they like the
underdog, the driven researcher fighting the medical
establishment. In this case, and with the benefit of hind-
sight, that approach may have led to an over-enthusiastic
and inadvertent promotion of some shaky science.
Of course, having evidence is not nearly enough. You
have to communicate the evidence. With CCSVI, the
patients—especially those who believed in this proced-
ure—won the communication battle, at least in the early
rounds. Scientists who had their doubts did not make
their arguments well, if at all. As noted previously, how-
ever, such a cautious and guarded approach is typical of
the discipline. In the absence of concrete evidence to
either support or debunk Zamboni’s hypothesis, scien-
tists generally were hesitant to make any definitive pro-
nouncements. While this hesitancy is understandable to
a point, scientists and journalists alike could resolve
some of these ‘cultural’ issues by making use of an inter-
locutor, an independent third party like the Science
Media Centres that have been established in Britain,
Australia, and Canada as well [18].
But, in the end, one thing that journalism and science
—two disparate professions—have in common is that
they are self-correcting over time. It’s not always a pretty
process but it is a necessary and informative one.
Politics and finances—Amy Zarzeczny
Canada is well known for its largely publicly funded
health care system. Health is an area of shared jurisdic-
tion between federal and provincial governments.
Through the Canada Health Act, the federal govern-
ment transfers funds to the provinces to administer their
provincial health care plans. Decisions regarding avail-
ability and public coverage for health services and pro-
ducts occur at various levels, and although processes
differ between provinces, a complex web of factors is
often engaged. These decision-making processes (andtheir political elements) are normally distinguished from
research funding decisions. As addressed in the follow-
ing section, the latter are generally made by institutions
and bodies with particular expertise in the area and with
the mandate to manage funding programs. The Canadian
MS liberation story is particularly interesting because of
the degree to which it brought these different spheres
together, reset the parameters, and directly engaged
politicians (at the behest of the public) in the research
funding realm.
Exactly why the CCSVI wave hit Canada so much
harder than other countries remains an open question.
Perhaps it is the fact that Canada has one of the highest
rates of MS in the world, at approximately 240/100,000
people [19], or perhaps the public health care system
means Canadians look more quickly to government to
take responsibility for health needs. Clearly the media’s
role was not insignificant, as the topic received more
attention in mainstream Canadian newspapers than any
other country, including even Italy [10]. By November
25, 2009, very early in this story’s evolution, an online
petition entitled “Support The Liberation Procedure
(The Zamboni Procedure)” which targeted Health
Canada had already garnered 17,624 signatures [20].
Supporters formed province-specific Facebook groups,
among other forms of social networking, to share infor-
mation and advocate.
Whatever the reason for its origin and momentum,
this considerable public pressure prompted action by
both federal and provincial policy-makers. At the federal
level Liberal Member of Parliament (MP) Kristy Duncan
introduced Bill C-280, An Act to establish a National
Strategy for Chronic Cerebrospinal Venous Insufficiency
(CCSVI) [21]. The Bill’s preamble referenced evidence
supporting CCSVI as a cause of MS and set out a frame-
work for establishing a national strategy, including clin-
ical trials. Although Bill C-280 was defeated on Second
Reading, it brought the debate into Parliament both in a
formal sense and in the political maneuvering that sur-
rounded it [22]. The degree to which Bill C-280 reflected
direct political involvement in the realm of science and
medical research raises interesting questions about the
priority setting process.
Perhaps partly in response to a perception that the
federal government was not moving with appropriate
speed in advancing CCSVI research and clinical applica-
tion, several provinces acted independently to allocate
funds directly [23]. British Columbia invested $700,000
over three years in a registry to track the experiences of
patients who had received treatment [24]. Similarly,
Alberta Health and Wellness set aside up to $1 million
(all figures are reported in Canadian dollars) to support
a three year observational study tracking the experiences
of Albertans [25]. Interestingly, the Government of
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trials, but only “if and when it is safe and ethical to
proceed” [26]. The Government of Newfoundland and
Labrador provided $400,000.00 to support an observa-
tional study of 30 patients who had received liberation
therapy. Using objective preliminary and post-procedural
tests, the study measured changes in the mental or phys-
ical status of patients over a twelve month period, as
compared to a control group of 10 who had not received
the treatment. The results confirmed “there were no
measurable objective medical changes in the observed
patients who underwent the CCSVI procedure” [27].
Of all the provinces, Saskatchewan arguably moved
the fastest and went the furthest in terms of devoting
public funds for clinical research into CCSVI. Rather
than taking an observational approach, Saskatchewan
focused quickly on interventional studies. On October
19, 2010, the Saskatchewan Government announced a
commitment of $5 million to clinical trials for liberation
therapy. Its neighboring province, Manitoba, subsequently
announced its intent to partner with Saskatchewan on this
trial with a matching $5 million [28]. Yukon Health and
Social Services similarly announced a $250,000 contribu-
tion. However, after assessing the proposed research initia-
tive and the specific projects that were applying for
funding, the Saskatchewan Health Research Foundation
(SHRF)—the scientific body normally tasked with judging
the nature and quality of such initiatives—concluded no
proposal should be funded at that time [29]. The
Saskatchewan Government was undeterred, and went on
to pursue partnering opportunities in other jurisdictions.
On January 12, 2012, Premier Brad Wall announced $2.2
million to allow Saskatchewan residents to participate in a
clinical trial at the Albany Medical Centre in Albany, New
York. Six-hundred eighty-two applications were subse-
quently received for an anticipated 86 spots for Saskatch-
ewan residents [30]. The first Saskatchewan patient to
participate received his surgery in August, 2012 [31].
The Saskatchewan Government’s commitment to
moving clinical trials forward has not waivered, notwith-
standing the lack of consensus around a number of key
issues including diagnostic techniques, whether there is
in fact a meaningful association between CCSVI and MS
and, if so, what the nature of that association might be
(e.g., cause versus effect). Indeed, in a September 23, 2011
press release, then Minister of Health Don McMorris
expressed, “‘Patients need answers as soon as possible . . .,’
and, ‘. . . [w]e owe it to them to explore every opportunity
to advance MS research and find answers about this treat-
ment’” [32].
Saskatchewan’s incidence rate of MS is approximately
340/100,000 people [33] With a population of just over
one million, roughly 3,400 people in Saskatchewan are
living with MS. In a province often characterized by itssmall-town feel and highly interconnected social net-
works, one needn’t look far before meeting someone
who is personally affected by MS, either directly, or
through a loved one. Accordingly, it is perhaps no won-
der this issue sparked so much public interest in the
province and got the attention of its political leaders.
Nevertheless it raises concerns about the relationship
between science and politics and about the role of the
media and social media in particular in shaping that
relationship.
Politics and science policy—Daryl Pullman
It would be naïve to believe that science proceeds inde-
pendent of political priorities and pressures. Any time
scientific institutions depend upon the public purse to
finance their endeavors, various political priorities will
influence the scientific agenda. As noted previously,
however, generally such broad agenda setting occurs
somewhat arms-length to the scientific process in
macro-level decisions about how much of the global
budget to allocate in support of scientific research.
Ideally once general allocation decisions are made it is
left to research institutions with the requisite knowledge,
experience and expertise to make the meso and micro-
level decisions for where those funds will be spent, pre-
sumably on the basis of available evidence. When polit-
ics intrudes on these more specific scientific decisions
the danger is that instead of evidence guiding policy,
policy and political pressure will guide what counts as
evidence.
In some respects the expert panel convened in the fall
of 2010 by CIHR in partnership with the MS Society of
Canada, was created to help manage the emerging public
and political pressures and to regain some control over
the scientific agenda with regard to CCSVI. The fact that
Alain Beaudet, president of the CIHR, decided to chair
the panel himself, is an indication of the high priority (at
least politically, if not scientifically) the file had assumed
in a relatively brief period of time. In August 2010, prior
to forming the expert panel, the CIHR and the MS So-
ciety convened a joint invitational meeting of top
researchers “to identify priorities for Canada that would
accelerate research and innovation on treatments for
MS” [33]. Despite the somewhat general mandate with
regard to MS treatments (plural), the focus was almost
exclusively on CCSVI. Nevertheless, the summary and
recommendations coming out of that meeting—including
the strong recommendation to establish the expert
panel—indicate a general determination to ensure that
scientific rigor would guide policy decisions rather than
the reverse. “Meeting participants were emphatic about
the crucial requirements for strong evidence based de-
cision making, at both medical and political levels . . .”
[34]. However, what serves as evidence in medicine, may
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commentary on the panel’s activities indicates that one
person’s “evidence” can be another’s “politics.” The subse-
quent activities of the expert panel and the manner in
which its activities were perceived bears this out, and
demonstrates just how difficult it can be to maintain a
strong commitment to scientific rigor in the face of relent-
less public and political pressure.
Unlike other members of the expert panel, I (DP) and
my colleague Bartha Knoppers—an expert in health law
— are neither research scientists nor clinicians. Hence
we have a somewhat unique perspective on how this
process unfolded within the expert panel. While we had
some sense of the political pressure on the panel in gen-
eral, we did not experience the same direct pressure as
did many of our clinical and scientific counter-parts.
Clinician members of the panel manage MS patients,
many of whom had gone abroad to receive liberation
therapy and were convinced of its efficacy. Other
patients were anxious to receive the therapy and were
openly frustrated when they could not get it at home.
Virtually all patients wanted a definitive clinical trial to
prove the case once and for all. Researchers on the panel
had their scientific credentials and personal integrity
questioned by CCSVI advocates who often posted com-
ments on web sites and were quoted in the media with
regard to industry sponsored research in which panel
members had been involved. The implication, if not
explicit charge, was that panel members had a vested
financial interest in dismissing CCSVI and liberation
therapy as scientifically unsound so as to maintain the
status quo.
In effect the expert panel functions as an oversight com-
mittee for on-going research related to venous anatomy
and MS. The panel consists of the principal investigators
of seven MS Society sponsored studies (four from Canada
and three from the US) that were carefully designed to in-
vestigate various aspects of the CCSVI hypothesis. Other
members included scientific leadership from CIHR and
the MS Society, a representative from the provinces and
territories, an international representative, as well as a
medical ethicist and a health law expert. The mandate of
the panel was to monitor and analyze preliminary and
final results from the seven on-going studies and from
related studies from around the world. If the accumulating
data was judged to provide “clear and convincing evi-
dence” in support of the CCSVI hypothesis, the panel
could recommend that the federal government proceed
with a clinical trial.
From the outset the panel’s work was closely scruti-
nized and critiqued. Kirsty Duncan, the MP who had
called for a national CCSVI strategy complained “. . .
CIHR put a political process in place instead of a scien-
tific process. Evidence was being willfully ignored fromthe literature, from scientific conferences, and from
returning Canadians treated for CCSVI” [22]. There is a
certain irony when a politician accuses scientists of play-
ing politics, and a degree of naiveté evident when litera-
ture, reports from scientific conferences, and anecdotal
reports from MS patients are apparently placed on the
same evidentiary plane. Indeed it is just such naïve views
about the nature of evidence that the expert panel was
designed to counter.
Nevertheless, there is little doubt that the decision to
convene the expert panel in the first place was as much a
political decision as a scientific one. Had the media
attention on CCSVI been less intense the concomitant
political pressure would not have materialized, and the
CIHR would not have felt compelled to make a public
demonstration that it was taking the issue seriously. The
on-going media and political pressure was evident as well
in the manner in which the panel conducted its activities.
For example, several of the studies being monitored by the
panel took extra-ordinary steps to send their ultra-sound
technicians for special training in the Zamboni scanning
protocol for venous anatomy. The concern was to avoid
further controversy should these studies fail to confirm
the CCSVI hypothesis, on the grounds that their imaging
technique was somehow flawed such that they failed to
see the confirming evidence. Again there is a certain irony
when an initial study that is almost universally dismissed
as methodologically flawed is used to set the standard for
future studies.
Despite the panel’s best efforts to remain politically
sensitive while maintaining scientific rigor, the unrelent-
ing media and political pressure were taking a toll. It is
my considered opinion that these pressures had an
increasing influence on the activities of the panel. When
the panel met on June 28, 2011 to review updates from
the seven studies as well as the results of a meta-analysis
of other CCSVI studies, it was aware that the federal
minister of health was waiting in the wings to receive an
update on the panel’s progress. Given that none of the
seven on-going studies had definitive results to report at
the time (most had not yet completed enrollment), any
ostensible “progress” would be based on the meta-
analysis. Those results were equivocal at best, and failed
to produce “clear and convincing evidence of CCSVI,”
the putative standard set at the initial scientific meeting
in August 2010 [35]. Results from autopsies conducted
on seven MS patients that indicated abnormal venous
anatomy for some patients were also presented, although
it was emphasized that these results were very prelimin-
ary, and it was too early to say what if anything this
might say with regard to the CCSVI hypothesis [36].
Even when combined with the results of the meta-
analysis, however, the evidence in support of the CCSVI
hypothesis remained less than clear.
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include a placebo arm in which participants received sham
surgery. Such a trial would present its own ethical chal-
lenges with regard to the available evidentiary standard
and the need to establish clinical equipoise. Even if equi-
poise could be established there would be issues of thera-
peutic misconception when patients enrolled in such a
study are convinced they would receive treatment, and
the resulting problems with achieving a fully informed
consent [37].
I am not at liberty to go into specific details of the
often animated discussion amongst panel members with
regard to what to make of the evidence that had been
presented. Suffice it to say that the federal Minister of
Health reported the next day that the panel had
endorsed a decision to proceed with a Phase I/II clinical
trial [38]. Since that time CIHR has announced funding
of a successful application to conduct this study [39].
In my view the pending meeting with the Minister of
Health had created something of a sense of urgency
about the panel’s deliberations, and an expectation that
some kind of a positive announcement would be helpful.
Thus the Phase I/II recommendation was in some sense
both a scientific and a political compromise. Such early
phase trials are generally designed to gather additional
evidence in support of a promising hypothesis, and to
see whether clinical equipoise can be established so as to
justify a larger Phase III study. In this case, while the
available evidence was equivocal at best, approving a
Phase I/II study provided a means by which to forestall
some of the continuing political pressure. However, this
was not the full-fledged Phase III study for which advo-
cates had been clamoring, and CIHR and the expert
panel have faced continuing criticism for failing to take
that step [40].
Summary
The Canadian experience with CCSVI presents an inter-
esting case study and raises important questions about
resource allocation and priority setting in the research
context. Indeed, we rarely see this kind of broad-scope
public momentum behind new drugs or therapies, and
we very rarely see governments so directly engaged in
pushing a particular research agenda, especially at such
an early stage (i.e., moving to clinical trials before there
is a strong evidentiary foundation, standardized diagnos-
tic approaches, management of the risks associated with
different treatment approaches, etc. [41]).
The priority setting tensions that emerge from this real-
ity are unquestionably complex. On what basis should we
decide to fund MS research versus other high-impact dis-
eases such as cancer or heart disease, two of the leading
causes of death for Canadians? What about rare but
equally devastating conditions that may not generate thesame level of public advocacy, or conditions that don’t
encourage the same degree of public sympathy [42]? What
about other areas of MS research where the evidence is
stronger? The degree to which evidence and expertise
should be the determining factors in these decisions and
the appropriate role for public pressure, advocacy and
interest groups are all matters of considerable debate.
These are by no means new challenges [43,44], but they
have been brought into the spotlight again by the evolving
MS liberation story [10,45,46].
One particularly salient aspect of how CCSVI has per-
meated political spheres is the influence of social media,
not only in terms of the rapid spread of information (or
misinformation), but also with its ability to mobilize
large numbers of people and capture the attention of
political leaders [47]. The current power of social media
represents a whole new level of citizen engagement and
advocacy, and emphasizes the importance of open
debate about the basis on which particular resource allo-
cation and priority setting policy choices are made in
scientific and medical research contexts, especially if
political leaders begin to play more direct roles in such
decisions. When dealing with the allocation of limited
public funds for research, decision-making should be
transparent, just, and at the very least, informed by
current evidence. Deliberative democracy cannot afford
to be high-jacked by a cyber-mob. However, the rapidity
with which new findings, whether speculative or proven,
make their way into the public sphere has undergone a
paradigm shift such that the process in which “evidence”
is manufactured may be changing irrevocably.
Gone are the days when researchers and clinicians can
rely on a few hours of “media training” to prepare them
for the off-chance they might be interviewed about some
aspect of their work. As the Canadian experience with
CCSVI illustrates so poignantly, the advent of the inter-
net and social media mean the ivory tower of academia
might be stormed at any moment by an interested,
enthusiastic, and motivated public. Researchers and clin-
icians must learn how to utilize these resources to
ensure the message that emerges is both balanced and
informed.
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